Related Experiment Video

Updated: Jun 13, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer

M Spears1, J Kenicer, A F Munro

  • 1Endocrine Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XR, Scotland.

Biomarkers in Medicine
|May 19, 2010
PubMed

Insights

Type I receptor tyrosine kinases (RTKs) are crucial in early breast cancer progression. This review examines their role in endocrine resistance, chemotherapy resistance, and their potential as predictive biomarkers in breast cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Type I receptor tyrosine kinases (RTKs) are integral to early breast cancer development.
  • Significant advancements in understanding RTKs have been made, yet their roles in endocrine and chemotherapy resistance remain incompletely defined.
  • The heterogeneity of breast cancer molecular subtypes necessitates personalized therapeutic strategies over a one-size-fits-all approach.

Purpose of the Study:

  • To review the human epidermal growth factor receptor (HER) family of proteins.
  • To explore the potential predictive or prognostic value of RTKs in early breast cancer.
  • To discuss the implications of RTKs in endocrine and chemotherapy resistance.

Main Methods:

  • Literature review of existing research on Type I RTKs in breast cancer.
  • Analysis of clinical trial data investigating RTK-targeted therapies and cytotoxic drugs.
  • Examination of studies focusing on molecular subtypes and differential treatment responses.

Main Results:

  • RTKs significantly influence early breast cancer progression.
  • Evidence suggests molecular subtypes exhibit varied responses to therapeutic interventions.
  • RTKs are implicated in the mechanisms of endocrine and chemotherapy resistance.

Conclusions:

  • The human epidermal growth factor receptor family plays a critical role in breast cancer.
  • Understanding RTK signaling is key to overcoming treatment resistance.
  • RTKs may serve as valuable predictive or prognostic biomarkers for early breast cancer management.

More Related Videos

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...